ClinicalTrials.gg
RecruitingNCT05654454Updated Aug 16, 2024

A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer

A Phase 3 interventional study of Bevacizumab and Paclitaxel in Non-Small Cell Lung Cancer, sponsored by Mabscale, LLC. Recruiting at 28 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by Mabscale, LLC · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
620
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 15 under way, 3 of them phase 3. Bevacizumab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
17th of 149
620 · median 56
Started
2023
the only one that year
Phase 3
29 of 150
1 open now
Primary completion
2026-12
later than 4 of 14 live
Registered
143rd of 150
by date

Among the 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung, this one is the 17th largest by planned enrollment of the 149 interventional ones that give a count, is the only one that started in 2023, is one of 29 in phase 3, reaches primary completion later than 4 of the 14 other live ones, and was the 143rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

BEV-III/2022 is a double-blind randomized multicenter clinical trial comparing efficacy of bevacizumab (manufactured by Mabscale, LLC) and paclitaxel plus carboplatin to Avastin® and paclitaxel plus carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC. The purpose of the study is to demonstrate equivalence of efficacy and safety of bevacizumab (manufactured by Mabscale, LLC) to Avastin®. Study includes pharmacokinetics assessment.

Read the detailed description

Bevacizumab is a monoclonal antibody currently being developed by Mabscale LLC, as a proposed biosimilar to Avastin®, which is approved as first line treatment in combination with carboplatin and paclitaxel for patients with unresectable, locally advanced, recurrent or metastatic non-squamous Non-Small Cell Lung Cancer. This randomized equivalence study is designed to meet the regulatory requirement for approval of a biosimilar product.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Male and female patients at least 18 years of age
  • Newly diagnosed Stage IIIB/C or IV non-small cell lung cancer (according to Revised Cancer Staging by American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) 8th edition) or recurrent non-small cell lung cancer (NSCLC)
  • or cytologically confirmed diagnosis of predominately non-squamous NSCLC
  • (ECOG) performance status 0 or 1
  • Be eligible to receive study treatment of bevacizumab, paclitaxel, and carboplatin based on local standard of care, for the treatment of advanced or non-squamous NSCLC
  • Presence of at least 1 measurable tumour as defined by modified (RECIST 1.1)
  • Neutrophils ≥ 1,5 × 10\^9/L
  • ≥ 100 × 10\^9/L
  • ≥ 90 g/L
  • level ≤ 1.5 × (ULN)
  • Aspartate-aminotransferase () and alanine-aminotransferase (ALT) levels \< 3 × ULN (\< 5 × ULN for patients with liver metastases)
  • Alkaline phosphatase level \< 3 × ULN (\< 5 × ULN for patients with liver or bone metastases)

Exclusion criteria

Exclusion Criteria:

  • Known sensitizing EGFR mutations or ALK translocation positive mutations
  • Evidence of a tumor that compresses or invades major blood vessels or tumor cavitation that is likely to bleed
  • Major surgery 28 days before inclusion into the study
  • Minor surgery 7 days before inclusion into the study
  • Stage II or higher of neuropathy or ototoxicity according to (CTCAE) v.5.0, excluding trauma
  • less than 6 months
  • to central nervous system or carcinomatous meningitis
  • Pregnancy or lactation
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
620 participants (estimated)

Study arms

  • Experimental
    Bevacizumab with Paclitaxel and Carboplatin

    Patients will begin Period 1 receiving bevacizumab combination therapy (Bevacizumab 15 mg/kg IV + Paclitaxel 175 mg/m2 + IV Carboplatin AUC 6 IV) on Day 0 of Cycle 1 for up to 6 cycles of therapy. Each cycle will consist of 3 weeks (21 days ± 3 days) and a cycle will start with the administration of bevacizumab (produced by Mabscale, LLC). In Period 2, eligible patients will continue to receive bevacizumab (produced by Mabscale, LLC) every 3 weeks as monotherapy.

    Drug: Bevacizumab · Drug: Paclitaxel · Drug: Carboplatin

  • Active comparator
    Avastin® with Paclitaxel and Carboplatin

    Patients will begin Period 1 receiving bevacizumab combination therapy ( Avastin® 15 mg/kg IV + Paclitaxel 175 mg/m2 IV + Carboplatin AUC 6 IV) on Day 0 of Cycle 1 for up to 6 cycles of therapy. Each cycle will consist of 3 weeks (21 days ± 3 days) and a cycle will start with the administration of bevacizumab (as Avastin®). In Period 2, eligible patients will continue to receive bevacizumab (Avastin®) every 3 weeks as monotherapy.

    Drug: Bevacizumab · Drug: Paclitaxel · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) at Week 18

    Objective response rate was assigned for a subject if the subject displayed either complete response (CR) or partial response (PR) per RECIST version 1.1 at Week 18, as assessed by independent radiological review committee (IRC).

    Time frame: 18 weeks from randomisation

Secondary outcomes

  1. Progression-free Survival (PFS)

    Progression-free survival was defined as the time from randomization to subsequent confirmed progression per RECIST version 1.1, or death (whichever occurred first), measured in weeks and months. For PFS assessment clinical progression (i.e., treatment discontinuation due to progression of disease) was also considered as an event.

    Time frame: At week 18 and 42 from randomisation

  2. Overall Survival (OS)

    Overall survival was defined as the time from randomization to subsequent death, measured in weeks and months.

    Time frame: At week 18 and 42 from randomisation

  3. Duration of response (DOR)

    Duration of responce was defined as the time from responce to treatment till progression or death.

    Time frame: 48 weeks

07

Study locations

22 of 28 sites recruiting
  • Arkhangelsk Clinical Oncological Dispensary
    Arkhangel'sk, Russian Federation
    Recruiting
    • Chapko · Contact
  • State Budget Healthcare Institution Ivanovo Regional Oncology Dispensary
    Ivanovo, Russian Federation
    Recruiting
    • Ponomareva · Contact
  • Kaluga Regional Clinical Oncology Dispensary
    Kaluga, Russian Federation
    Recruiting
    • Kudryavtsev · Contact
  • Regional clinical oncological dispensary n.a.Sigal
    Kazan', Russian Federation
    Recruiting
    • Safin · Contact
  • Burdenko Main Military Clinical Hospital
    Moscow, Russian Federation
    Recruiting
    • Smolin · Contact
  • Hadassah Medical Moscow
    Moscow, Russian Federation
    Withdrawn

    Not enrolling at this site — choose another above.

  • National Medical Oncology Research Center n.a. N.N. Blokhina
    Moscow, Russian Federation
    Not yet recruiting
    • Breder · Contact
  • Murmansk Regional Clinical Hospital
    Murmansk, Russian Federation
    Recruiting
    • Korelskaya · Contact
  • Nizhny Novgorod Regional Oncology Dispensary
    Nizhny Novgorod, Russian Federation
    Recruiting
    • Matrosova · Contact
  • Novosibirsk oncologic dispensary
    Novosibirsk, Russian Federation
    Recruiting
    • Kozlov · Contact
  • Omsk clinical oncologic dispensary
    Omsk, Russian Federation
    Recruiting
    • Zimina · Contact
  • Perm Edge Clinical Hospital
    Perm, Russian Federation
    Not yet recruiting
    • Trefilova · Contact
  • Perm Regional Clinical Hospital
    Perm, Russian Federation
    Not yet recruiting
    • Trefilova · Contact
  • Euromedservice medical center
    Pushkin, Russian Federation
    Recruiting
    • Pen'kov · Contact
  • Clinical Hospital RZD-Medicine
    Saint Petersburg, Russian Federation
    Recruiting
    • Vasiliev · Contact
  • Euro Cityclinic
    Saint Petersburg, Russian Federation
    Recruiting
    • Orlov · Contact
  • Leningrad regional clinical hospital (prev.Oncological dispensary n.a.Roman)
    Saint Petersburg, Russian Federation
    Recruiting
    • Belogortsev · Contact
  • Leningrad regional clinical hospital
    Saint Petersburg, Russian Federation
    Recruiting
    • Smagina · Contact
  • National Medical Research Center of Oncology N.A. N.N. Petrov
    Saint Petersburg, Russian Federation
    Recruiting
    • Poltoratsky · Contact
  • Northwestern Center for Evidence-Based Medicine
    Saint Petersburg, Russian Federation
    Recruiting
    • Schmelev · Contact
  • Medical University "Reaviz"
    Samara, Russian Federation
    Recruiting
    • Kopp · Contact
  • Smolensk oncologic dispensary
    Smolensk, Russian Federation
    Recruiting
    • Povaga · Contact
  • Smolensk Regional Clinical Hospital
    Smolensk, Russian Federation
    Recruiting
    • Haykin · Contact
  • Tverskoy Regional Oncological Dispensary
    Tver, Russian Federation
    Recruiting
    • Dergunov · Contact
  • Bashkir State Medical University
    Ufa, Russian Federation
    Not yet recruiting
    • Sakaeva · Contact
  • Oblastnoy Clinical Oncological Dispansery
    Veliki Nóvgorod, Russian Federation
    Not yet recruiting
    • Mancirev · Contact
  • Volgograd Regional Clinical Oncology Dispensary
    Volgograd, Russian Federation
    Recruiting
    • Kovalenko · Contact
  • Regional Clinical Oncological Hospital
    Yaroslavl, Russian Federation
    Recruiting
    • Belonogov · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Dec 2026, 43 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 43 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2022
First posted
Dec 16, 2022
StartActual
May 31, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Aug 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05654454
Lead sponsor
Mabscale, LLC
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
May 31, 2023
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Aug 16, 2024

Study contacts

Alexander Generalov, MD
Contact
generalov.a@benerix.ru
+74997149289

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Paclitaxel · Carboplatin

Start the discussion